These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 19024280)

  • 41. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials.
    Gerlag DM; Tak PP
    Best Pract Res Clin Rheumatol; 2008 Apr; 22(2):311-23. PubMed ID: 18455687
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.
    Popa C; Netea MG; de Graaf J; van den Hoogen FH; Radstake TR; Toenhake-Dijkstra H; van Riel PL; van der Meer JW; Stalenhoef AF; Barrera P
    J Rheumatol; 2009 Apr; 36(4):724-30. PubMed ID: 19273452
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Administration of monoclonal antibodies to B-lymphocytes (rituximab) in rheumatoid arthritis in Russia].
    Nasonov EL; Lukina GV; Sigidin IaA; Bazevich LA; Zlobina TI; Kamalova RG; Kniazeva LA; Mazurov VI; Men'shikova LV; Sizikov AE; Smirnova EA; Fofonova NA; Shabalina TV; Shkil' NV; Iakushin SS
    Ter Arkh; 2008; 80(8):57-62. PubMed ID: 18807543
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis.
    Radovits BJ; Fransen J; Eijsbouts A; van Riel PL; Laan RF
    Rheumatology (Oxford); 2009 Aug; 48(8):906-10. PubMed ID: 19478038
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy.
    Rosner I; Haddad A; Boulman N; Feld J; Avshovich N; Slobodin G; Rozenbaum M
    Rheumatology (Oxford); 2007 Sep; 46(9):1508; author reply 1508-9. PubMed ID: 17684027
    [No Abstract]   [Full Text] [Related]  

  • 46. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis.
    Yazici Y; Krasnokutsky S; Barnes JP; Hines PL; Wang J; Rosenblatt L
    J Rheumatol; 2009 May; 36(5):907-13. PubMed ID: 19332636
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TRU-015, a fusion protein derived from an anti-CD20 antibody, for the treatment of rheumatoid arthritis.
    Rubbert-Roth A
    Curr Opin Mol Ther; 2010 Feb; 12(1):115-23. PubMed ID: 20140823
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects.
    Quartuccio L; Lombardi S; Fabris M; Masolini P; Saracco M; Pellerito R; De Vita S
    Ann N Y Acad Sci; 2009 Sep; 1173():692-700. PubMed ID: 19758217
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis.
    Gonzalez-Gay MA; Garcia-Unzueta MT; Berja A; Vazquez-Rodriguez TR; Gonzalez-Juanatey C; de Matias JM; Martin J; Dessein PH; Llorca J
    Ann Rheum Dis; 2008 Nov; 67(11):1644-6. PubMed ID: 18854515
    [No Abstract]   [Full Text] [Related]  

  • 52. Anti-TNF-induced lupus.
    Williams EL; Gadola S; Edwards CJ
    Rheumatology (Oxford); 2009 Jul; 48(7):716-20. PubMed ID: 19416947
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Rituximab (Mabthera)--new approach in treatment of rheumatoid arthritis].
    Anić B
    Reumatizam; 2007; 54(2):72-3. PubMed ID: 18351146
    [No Abstract]   [Full Text] [Related]  

  • 54. [Stable remission of early active rheumatoid arthritis treated with etanercept (Enbrel)].
    Kaliterna DM
    Reumatizam; 2008; 55(2):60-1. PubMed ID: 19024277
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells.
    Tanino M; Matoba R; Nakamura S; Kameda H; Amano K; Okayama T; Nagasawa H; Suzuki K; Matsubara K; Takeuchi T
    Biochem Biophys Res Commun; 2009 Sep; 387(2):261-5. PubMed ID: 19577537
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic and genomic predictors of anti-TNF response.
    Prajapati R; Plant D; Barton A
    Pharmacogenomics; 2011 Nov; 12(11):1571-85. PubMed ID: 22044414
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ocrelizumab: a step forward in the evolution of B-cell therapy.
    Kausar F; Mustafa K; Sweis G; Sawaqed R; Alawneh K; Salloum R; Badaracco M; Niewold TB; Sweiss NJ
    Expert Opin Biol Ther; 2009 Jul; 9(7):889-95. PubMed ID: 19463076
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Safety of rituximab in patients with rheumatoid arthritis].
    Morović-Vergles J
    Reumatizam; 2010; 57(2):158-60. PubMed ID: 21875022
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab.
    Fleischmann RM
    Semin Arthritis Rheum; 2009 Feb; 38(4):265-80. PubMed ID: 18336874
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Emerging therapeutics for rheumatoid arthritis.
    Bingham CO
    Bull NYU Hosp Jt Dis; 2008; 66(3):210-5. PubMed ID: 18937634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.